Altogen Biosystems [ Ссылка ] provides the Lipid In Vivo Transfection Kit [ Ссылка ]. Efficient in vivo delivery of nucleic acids and proteins is possible with the Altogen® Biosystems cationic lipid transfection reagent.

This product falls into the category of the versatile in vivo transfection kits that Altogen® Biosystems offers. Degradation of cargo molecules is minimized and delivery efficiency is maximized for any negatively charged molecules (DNA, RNA).

-Lipids refer to a class of molecules that occur naturally and include sterols, waxes, fats, vitamins that are fat soluble, monoglycerides, phospholipids and many others.

A positively charged head and one or two hydrocarbon chains encompass the structure of cationic lipids, various models of which are shown. The dynamic between the charged head and phosphate backbone of a nucleic acid allows for DNA condensation.

-Summary:
All Altogen® In Vivo Transfection Kits supplied with pre-optimized ready-to-run transfection protocols that eliminate the need for extensive transfection testing and optimization experiments

Lipid-based in vivo transfection reagent is a proprietary, animal-origin-free formulation of chemically engineered liposomes optimized for siRNA, shRNA, miRNA, plasmid DNA, and small protein in vivo delivery.

-Mechanism of Action:
Cationic lipid reagents provide one of the most robust and effective tool for creating transfection complexes with negatively charged cargo (bind spontaneously to the liposomes that have a positive charge), while proprietary formulation allows to minimize complex size providing effective delivery into target tissues.

-Product Details:
Lipid-based reagent
Complexes are stable in serum for 16 hours
Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration
Efficient siRNA and plasmid DNA delivery via IV, IT, or direct subcutaneous tumor injection (various tumor types)
Minimal toxicity
Functionally tested in mice and rats
Applicable for plasmid DNA/siRNA co-injection
Developed and manufactured by Altogen Biosystems
Modes of administration:
Systemic intravenous (i.v.) injection
Direct intratumoral (i.t.) injection
Intraperitoneal (i.p.) injection

-Tissue-Targeting.
-Product Details:
Our kits are easy to use and effective: Mix, incubate, dilute, and inject!
Our kits allow for sustained mRNA knockdown after a single siRNA injection
Target various organs through different administration routes.
There is very low in vivo toxicity and it is safe to use as there is no detectable inflammatory response.
Used for preclinical research worldwide!

-Systemic administration (i.v.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol.
-Intratumoral administration (i.t.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol.
-Systemic administration (i.v.) of Lipid In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol.
-Summary:
Lipid-based reagent
Complexes are stable in serum for 16 hours
Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration
Efficient siRNA and plasmid DNA delivery via IV, IP, and direct subcutaneous tumor injection (various tumor types)
Minimal toxicity
Functionally tested in mice and rats
Applicable for plasmid DNA/siRNA co-injection
Developed and manufactured by Altogen Biosystems

Connect to Altogen Biosystems:
LinkedIn - [ Ссылка ]
Twitter - [ Ссылка ]
Facebook - [ Ссылка ]

свернуть